Objectif
Inhibitors of metalloproteinases have shown a high therapeutic potency in preliminary clinical trials. However, unacceptable side-effects are associated, which are relative to recently discovered ADAMS and "non classical" effects of MMPs. This project aims at defining the best MMP inhibition profiles for cancer therapy by
1) a comprehensive assessment of metalloprateinase activities and functions at both physiological and tumour progression level, i.e. by using first inhibition inhibitors as probe;
2) designing new metalloproteinase inhibitors on the basis of inhibitor-enzyme complex 3-D structures and on the biological activities to be tackled;
3) assessing the benefit of combining MMP inhibitors with serine proteases inhibitors designed on a similar basis.
Champ scientifique
Appel à propositions
Data not availableRégime de financement
CSC - Cost-sharing contractsCoordinateur
4000 LIEGE
Belgique